G3BP1 and bladder transitional cell carcinoma: EGCG, a polyphenol isolated from tea leaves, inhibits G3BP1 by binding to endogenous G3BP1 in tumor cells.[25] Therefore, we investigated the potential use of EGCG to treat patients with BLCA, as EGCG has previously been used in patients with other cancer types.[26] As expected, EGCG downregulated p‐AktThr308 and p‐AktSer473 and upregulated MHC‐I in a dose‐dependent manner in both UMUC3 and MB49 cells (Figure 8A–C).